Clinical Trial

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Study acronym: DUET ENCORE-CD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).
Protocol Amendment History 4 changes
notable Trial sites expanded: 22 -> 55 locations 2026-08-01
notable Trial sites expanded: 5 -> 22 locations 2026-07-07
critical Recruitment opened 2026-06-09
notable Trial sites expanded: 0 -> 5 locations 2026-06-09
Trial Details
NCT Number NCT07577843
Lead Sponsor Janssen Research & Development, LLC
Conditions Crohn Disease
Enrollment 460 participants
Start Date 2026-05-22
Primary Completion 2028-06-12 (estimated)
Study Completion 2030-07-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-31